CardioExchange Archive

March 9th, 2015

Selections from Richard Lehman’s Literature Review: March 9th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effects of low BP in cognitively impaired elderly patients taking antihypertensive drugs and the effects of blood-pressure lowering on CV risk according to baseline BMI.

---

January 22nd, 2015

New Device to Lower Resistant Hypertension Shows Early Promise

Larry Husten, PHD

A novel implantable device appears to show early promise in the treatment of resistant hypertension. The “Coupler” device from ROX Medical is about the size of a paper clip and is delivered via a catheter to the upper thigh, where it creates an anastomosis between the distal external iliac vein and artery, thereby mechanically lowering […]

---

September 30th, 2013

Selections from Richard Lehman’s Literature Review: September 30th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the RE-ALIGN trial of dabigatran vs. warfarin in patients with mechanical heart valves, general population echo screening and long-term survival, and antihypertensives and breast cancer risk among middle aged women.

---

August 29th, 2013

Managing Hypertension – Not as Easy as It Once Seemed

Paul A. Bergl, MD

A Chief Resident surveys the rapidly changing landscape of hypertension management.

---

February 2nd, 2013

European Heart Journal Retracts Main Paper of the Kyoto Heart Study

Larry Husten, PHD

The 2009 report of the Kyoto Heart Study on the add-on effect of valsartan in hypertension has been retracted with a terse comment by the editors of the European Heart Journal.

---

September 25th, 2012

Another One Bites the Dust: Diovan Patent Expires but Generic Valsartan Is MIA

Larry Husten, PHD

Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan HCT, the combination of valsartan and hydrochlorothiazide, was recently launched by generic drug maker Mylan. As reported on Pharmalot, Ranbaxy, the embattled generic drug maker, holds the exclusive […]

---